Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

J Endocrinol Invest. 2016 Jul;39(7):807-34. doi: 10.1007/s40618-016-0434-8. Epub 2016 Mar 11.


Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

Keywords: Adherence; Androgen deprivation; Aromatase inhibitors; Bisphosphonates; Denosumab; Drug-induced osteoporosis; Fracture; Length of therapy; Male osteoporosis; Non-responder; Osteoporosis; SERMs; Side effects; Strontium ranelate; Teriparatide; Treatment.

MeSH terms

  • Bone Density / drug effects*
  • Bone Density Conservation Agents / therapeutic use
  • Consensus
  • Endocrinologists
  • Female
  • Humans
  • Italy
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporotic Fractures / prevention & control*


  • Bone Density Conservation Agents